^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Gastric Cancer

Related cancers:
9h
miR-122-IGF-1R signaling allied through the dysregulated lncRNA MALAT-1 expression in gastric carcinoma. (PubMed, Toxicol Rep)
Prominent MALAT-1 levels may assist as an indicator of metastasis in GC, and that miR-122-IGF-1R expression is associated via reduced MALAT-1 signaling. Finally, PEG-DOX may be an excellent option for GC therapy.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • JAK2 (Janus kinase 2) • MALAT1 (Metastasis associated lung adenocarcinoma transcript 1) • MIR122 (MicroRNA 122)
9h
Probiotic-derived ferrichrome induces DDIT3-mediated antitumor effects in esophageal cancer cells. (PubMed, Heliyon)
However, 14 days of intraperitoneal administration of 20-mg/kg 5-fluorouracil (5-FU), but not 20-mg/kg ferrichrome, induced weight loss and myelosuppression in both young and aged mice. Our findings indicate that ferrichrome induces DNA damage-inducible transcript-3, thereby producing anti-tumor effects, including cell cycle arrest and apoptosis, with minimal adverse effects in esophageal cancer cells. This illustrates the high potential of ferrichrome as an anti-tumor drug against esophageal carcinoma.
Journal
|
CASP9 (Caspase 9) • DDIT3 (DNA-damage-inducible transcript 3)
|
5-fluorouracil
9h
JAK3/STAT5 signaling-triggered upregulation of PIK3CD contributes to gastric carcinoma development. (PubMed, J Cell Commun Signal)
These observations may setup a new crosstalk between tumor inflammatory microenvironment, IL2/JAK3/STAT5 signaling and PI3K/AKT signaling. Targeting PIK3CD may be a promising therapy strategy for GC.
Journal
|
PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta) • PIK3CB (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) • JAK3 (Janus Kinase 3) • STAT5A (Signal Transducer And Activator Of Transcription 5A)
|
PIK3CD expression
11h
The Combination of Afatinib With Dasatinib or Miransertib Results in Synergistic Growth Inhibition of Stomach Cancer Cells. (PubMed, World J Oncol)
Of various human epidermal growth factor receptor (HER) inhibitors, only the anti-HER2 monoclonal antibody (mAb) Herceptin/trastuzumab and the antibody-drug conjugate trastuzumab deruxtecan (T-Dxd) has been approved for the treatment of patients with stomach cancer...Of various HER inhibitors, the irreversible pan-HER family inhibitors (e.g., afatinib) were more effective than the reversible dual epidermal growth factor receptor (EGFR)/HER2 tyrosine kinase inhibitor (TKI) lapatinib and the EGFR-specific TKI erlotinib in inhibiting the growth of HSCCLs. Of agents targeting different downstream cell signaling molecules, dasatinib targeting Ab1/Src/C-Kit, trametinib targeting MERK1/2 and miransertib targeting AKT1/2/3 inhibited growth of majority of HSCCLs, with the IC50 values ranging from 2 nM to 7 µM...Treatment with neratinib, afatinib, dinaciclib, dasatinib, stattic, miransertib and paclitaxel significantly inhibited migration of stomach cancer cells. Interestingly, treatment with a combination of afatinib and dasatinib or afatinib and miransertib resulted in synergistic and additive growth inhibition of stomach cancer cells. These results suggest that treatment with a combination of these agents may be of therapeutic value in stomach cancer and warrants further investigations.
Journal
|
ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD44 (CD44 Molecule)
|
Herceptin (trastuzumab) • Mekinist (trametinib) • erlotinib • Gilotrif (afatinib) • dasatinib • paclitaxel • lapatinib • Nerlynx (neratinib) • Enhertu (fam-trastuzumab deruxtecan-nxki) • dinaciclib (MK-7965) • miransertib (MK-7075)
11h
Targeting the receptor tyrosine kinase MerTK shows therapeutic value in gastric adenocarcinoma. (PubMed, Cancer Med)
Our findings demonstrate the potential value of MerTK as a prognostic biomarker for gastric adenocarcinoma. Targeting MerTK may become a new treatment option, especially for patients with advanced tumors, and may overcome resistance to established chemotherapies.
Journal
|
MERTK (MER Proto-Oncogene, Tyrosine Kinase)
|
MERTK expression
|
5-fluorouracil • UNC2025
11h
Identification of Hub Genes and Potential Pathogenesis in Gastric Cancer Based on Integrated Gene Expression Profile Analysis. (PubMed, Asian Pac J Cancer Prev)
SPP1, INHBA, MMP7, THBS2, and FAP were identified as prospective biomarkers and therapeutic targets for GC that might be utilized for prognostic evaluation and scheme selection.
Journal • Gene Expression Profile
|
SPP1 (Secreted Phosphoprotein 1) • THBS2 (Thrombospondin 2) • MMP7 (Matrix metallopeptidase 7)
12h
Associations of PD-1 and PD-L1 gene polymorphisms with cancer risk: a meta-analysis based on 50 studies. (PubMed, Aging (Albany NY))
The rs7421861 polymrophism decreased cancer risk among Caucasians, rather than the rs10815225 elevated cancer risk. Our results supported that PD-1 and PD-L1 SNPs were dramatically correlated with cancer risk.
Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
|
PD-L1 rs2297136 • PD-L1 rs4143815
12h
The necroptosis-related signature and tumor microenvironment immune characteristics associated with clinical prognosis and drug sensitivity analysis in stomach adenocarcinoma. (PubMed, Aging (Albany NY))
This investigation provides a robust methodological advance in prognosticating and personalizing immunotherapy for STAD, leveraging quantitatively derived tumor cluster risk scores. It posits the use of necroptosis-related lncRNAs as pivotal molecular beacons for guiding therapeutic strategies and enhancing clinical outcomes in STAD.
Journal • IO biomarker
|
CD44 (CD44 Molecule)
|
CD44 expression
13h
A Natural Peptide from A Traditional Chinese Medicine Has the Potential to Treat Chronic Atrophic Gastritis by Activating Gastric Stem Cells. (PubMed, Adv Sci (Weinh))
It is further shown that the peptide exerts its functions by stabilizing the EGF-EGFR complex and specifically activating the downstream ERK and Stat1 signaling. Overall, these findings advance the understanding of AG pathogenesis and open a new avenue for AG treatment.
Journal
|
EGFR (Epidermal growth factor receptor) • STAT1 (Signal Transducer And Activator Of Transcription 1)
17h
Noscapine and Apoptosis in Breast and Other Cancers. (PubMed, Int J Mol Sci)
Gene expression was higher in tumor than in normal tissue, including the BAX expression levels in lung, ovary, endometrium, colon, stomach, and glioblastoma patients; BCL2L1 expression in endometrium, colon, and stomach patients; CASP8 gene expression levels in lung, endometrium, colon, stomach, and glioblastoma patients; RELA in colon, stomach, and glioblastoma patients; and NFKBIA in glioblastoma patients. It can be concluded that noscapine affected genes and proteins related to apoptosis in cancer cell lines and several types of cancer patients.
Review • Journal
|
BCL2L1 (BCL2-like 1) • BAX (BCL2-associated X protein) • CASP8 (Caspase 8) • CASP9 (Caspase 9) • NFKBIA (NFKB Inhibitor Alpha 2) • RELA (RELA Proto-Oncogene)
|
BAX expression
17h
Gastric Cancer in the Era of Epigenetics. (PubMed, Int J Mol Sci)
Ongoing clinical trials are currently evaluating the efficacy of next-generation epigenetic drugs, displaying promising outcomes. Various approaches including multiple miRNA inhibitors or targeted nanoparticles carrying epigenetic drugs are being designed to enhance existing treatment efficacy and overcome treatment resistance.
Review • Journal
|
NNMT (Nicotinamide N-Methyltransferase)
17h
Differential Gene Regulatory Network Analysis between Azacitidine-Sensitive and -Resistant Cell Lines. (PubMed, Int J Mol Sci)
Our results suggest that controlling the identified genes (e.g., the metallothionein gene family) and "cellular response"-related pathways ("cellular response to zinc ion", "cellular response to copper ion", and "cellular response to cadmium ion", where the enriched functional-related genes are MT2A, MT1F, MT1G, and MT1E) may provide crucial clues to address azacitidine resistance in patients with AML. We expect that our strategy will be a useful tool to uncover patient-specific molecular interplay that provides crucial clues for precision medicine in not only gastric cancer but also complex diseases.
Preclinical • Journal
|
GRB7 (Growth Factor Receptor Bound Protein 7) • IL18 (Interleukin 18) • ELF3 (E74 Like ETS Transcription Factor 3) • MT2A (Metallothionein 2A)
|
azacitidine
18h
Sympathetic Nervous Influences Are Negative Prognostic Factors in Stomach Cancer. (PubMed, Life (Basel))
In addition, the analysis of intra-tumoral sympathetic fibers showed a better survival rate (83%) for patients with a low value of density compared to patients with increased density, in whom the survival rate was only 24%. (4) The findings of this study indicate that patients with stomach cancer have a more unfavorable prognosis when they have a higher density of sympathetic nerve fibers and an increased expression of beta 2 adrenergic receptors inside the tumor.
Journal
|
ADRB2 (Adrenoceptor Beta 2)
19h
Chromatin Remodeling-Related PRDM1 Increases Stomach Cancer Proliferation and Is Counteracted by Bromodomain Inhibitor. (PubMed, J Pers Med)
Through applying systematic bioinformatic analysis, we determined that out of 31 chromatin remodeling factors in six gastrointestinal cancers, only PR/SET domain 1 (PRDM1) showed both expression alteration and prognosis prediction. Analyses on pathways, therapies, and mediators showed that cell cycle, bromodomain inhibitor IBET151, and BET protein BRD4 were, respectively involved in PRDM1-high stomach cancer, while cell line experiments validated that PRDM1 knockdown in human stomach cancer cell line SNU-1 decreased its proliferation, BRD4 expression, and responsiveness to IBET151; accordingly, these results indicate the contribution by PRDM1 in stomach cancer formation and its association with BRD4 modulation as well as BET inhibitor treatment.
Journal
|
BRD4 (Bromodomain Containing 4) • PRDM1 (PR/SET Domain 1)
|
I-BET151
21h
HER2 and PD-L1 Expression in Gastric and Gastroesophageal Junction Cancer: Insights for Combinatorial Targeting Approaches. (PubMed, Cancers (Basel))
While the therapeutic implications of these observations remain unknown, these findings suggest that combination strategies targeting HER2 and PD-L1 might be directed toward distinct tumor subclones. The herein disclosed region-specific biomarker expression patterns may have important therapeutic and prognostic impacts, warranting further evaluation.
Journal • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • HER-2 positive • HER-2 overexpression • HER-2 expression • HER-2 positive + PD-L1 expression • PD-L1 expression + HER-2 overexpression • PD-L1 expression + HER-2 expression
22h
Comprehensive analysis of the prognostic value and immunological role of IDO1 gene in pan-cancer. (PubMed, Eur J Med Res)
The clinical treatment of IDO1 is now better supported by a theoretical basis and guidelines provided by our study.
Journal • Tumor mutational burden • IO biomarker • Pan tumor
|
TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • IDO1 (Indoleamine 2,3-dioxygenase 1)
|
IDO1 expression
1d
: A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=381, Recruiting, Hutchmed | Trial completion date: Sep 2023 --> Dec 2025 | Trial primary completion date: Sep 2023 --> Dec 2025
Trial completion date • Trial primary completion date • Metastases
|
PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • IFNA1 (Interferon Alpha 1)
|
PD-L1 expression • MSI-H/dMMR • ROS1 fusion • ALK-ROS1 fusion
|
Tyvyt (sintilimab) • Fruzaqla (fruquintinib)
1d
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer (clinicaltrials.gov)
P1/2, N=232, Recruiting, AstraZeneca | Trial completion date: Apr 2025 --> Jul 2025 | Trial primary completion date: Jan 2025 --> Jul 2025
Trial completion date • Trial primary completion date • Metastases
|
PD-L1 expression
|
sabestomig (AZD7789)
1d
Enrollment change • Trial withdrawal • Combination therapy • Metastases
|
balstilimab (AGEN2034) • zalifrelimab (UGN-301)
1d
EDGE-Gastric: A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies (clinicaltrials.gov)
P2, N=360, Recruiting, Arcus Biosciences, Inc. | N=200 --> 360 | Trial completion date: Nov 2025 --> Jun 2027 | Trial primary completion date: Sep 2025 --> Sep 2026
Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
5-fluorouracil • oxaliplatin • Yutuo (zimberelimab) • leucovorin calcium • domvanalimab (AB154) • quemliclustat (AB680)
1d
New trial
1d
KEYNOTE-877: Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab (clinicaltrials.gov)
P1/2, N=323, Active, not recruiting, RAPT Therapeutics, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Jan 2025 | Trial primary completion date: Jul 2023 --> Sep 2024
Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • tivumecirnon (FLX475)
1d
Exosomal circSTRBP from cancer cells facilitates gastric cancer progression via regulating miR-1294/miR-593-3p/E2F2 axis. (PubMed, J Cell Mol Med)
The stability of circSTRBP was assessed by actinomycin D and Ribonuclease R treatment...Additionally, exosomal circSTRBP promoted the tumour growth of GC cells in the xenograft model. Exosomal circSTRBP is implicated in the progression of GC by modulating the activity of miR-1294/miR-593-3p/E2F2 axis.
Journal
|
E2F2 (E2F Transcription Factor 2)
|
dactinomycin
1d
Journal • PD(L)-1 Biomarker • IO biomarker
|
MSI (Microsatellite instability)
1d
Journal
|
IFNG (Interferon, gamma) • IL10 (Interleukin 10) • VIM (Vimentin) • IL17A (Interleukin 17A)
|
VEGFA expression • VIM expression
1d
Nomogram for Predicting Infectious Complications Following Curative Gastrectomy Using Clinical and Laboratory Parameters. (PubMed, Anticancer Res)
This study presents a novel estimating model for infectious complications following curative gastrectomy. The utilization of this model in patient discharge planning can aid in identifying individuals who require additional treatment, thereby minimizing unexpected readmissions.
Journal
|
CRP (C-reactive protein)
1d
Gastric Cancer With the Increased Nicotinamide N-methyltransferase-positive Stromal Cells Includes Unfavorable Prognosis-related Cancer-associated Fibroblasts. (PubMed, Anticancer Res)
The higher proportion of NNMT-positive cancer stromal cells in gastric cancer serves as an indicator for identifying unfavorable prognostic CAFs that show a global decrease in H3K4me3/H3K27me3. This facilitates research on the nature of these cells and their characteristics.
Journal • Stroma
|
LOXL2 (Lysyl Oxidase Like 2) • NNMT (Nicotinamide N-Methyltransferase)
1d
The CRP-albumin-lymphocyte (CALLY) Index Is an Independent Prognostic Factor for Gastric Cancer Patients who Receive Curative Treatment. (PubMed, Anticancer Res)
The CALLY score was an independent prognostic factor for patients with gastric cancer. Our results suggest that the CALLY index is a promising tool for assessing inflammation and nutritional status in patients undergoing gastric cancer treatment and management.
Journal
|
CRP (C-reactive protein)
|
Albumin-L
1d
Hsa_circTCF25 Facilitates Oncogenesis in Gastric Cancer Cells by Modulating miR-149 Expression. (PubMed, Anticancer Res)
circTCF25 may have prognostic value and an oncogenic role in gastric cancer. A circTCF25-miR-149 RNA regulatory network was established which may provide novel biomarkers or potential therapeutic targets for treating gastric cancer.
Journal
|
MIR149 (MicroRNA 149)
1d
Activation of the FOXM1/ASF1B/PRDX3 axis confers hyperproliferative and antioxidative stress reactivity to gastric cancer. (PubMed, Cancer Lett)
Treatment with thiostrepton, a FOXM1 inhibitor, not only suppressed ASF1B expression, but also inhibited GC progression...The crucial role of ASF1B-regulated PRDX3 in GC cell proliferation and oxidative stress balance was also elucidated. In summary, our study suggests that the FOXM1-ASF1B-PRDX3 axis is a potential therapeutic target for treating GC.
Journal
|
FOXM1 (Forkhead Box M1) • ASF1B (Anti-Silencing Function 1B Histone Chaperone)
|
ASF1B overexpression
|
thiostrepton (RSO-021)
1d
Epstein-Barr virus suppresses N6-Methyladenosine modification of TLR9 to promote immune evasion. (PubMed, J Biol Chem)
In clinical lymphoma samples, the expression of METTL3, YTHDF1 and TLR9 was highly correlated with immune cells infiltration. This study reveals a novel mechanism that EBV represses the important innate immunity molecule TLR9 through modulating the host m6A modification system.
Journal • IO biomarker
|
TLR9 (Toll Like Receptor 9) • METTL3 (Methyltransferase Like 3) • YTHDF1 (YTH N6-Methyladenosine RNA Binding Protein 1)
|
TLR9 expression
1d
YTHDF1 Promotes Proliferation and Inhibits Apoptosis of Gastric Cancer Cells via Upregulating TCF7 mRNA Translation. (PubMed, Front Biosci (Landmark Ed))
We found that YTHDF1 was upregulated in GC and that YTHDF1 could promote GC progression through modulating the translational efficiency of TCF7. Taken together, these findings may provide a novel therapeutic target for GC.
Journal
|
TCF7 (Transcription Factor 7) • YTHDF1 (YTH N6-Methyladenosine RNA Binding Protein 1)
1d
Construction of a Human Immune Library from Gallbladder Cancer Patients for the Single-Chain Fragment Variable (scFv) Antibody Selection against Claudin 18.2 via Phage Display. (PubMed, Antibodies (Basel))
After three rounds of panning, we were able to identify clones with specificity against claudin 18.2. GALLBLA1 can contribute to the selection, isolation, and recombinant production of new human mAbs candidates for the treatment of gastrointestinal cancers.
Journal
|
CLDN18 (Claudin 18)
1d
Unraveling the causal role of immune cells in gastrointestinal tract cancers: insights from a Mendelian randomization study. (PubMed, Front Immunol)
These traits include "CCR2 on CD14- CD16+ monocyte," "CD19 on IgD+ CD38-," "CD19 on IgD+ CD38- naive," "CD25hi CD45RA+ CD4 not Treg AC," "CD27 on unsw mem," "CD28 on CD39+ activated Treg," and "CD45 on CD4+." This study elucidates a causal link between immune cells and gastrointestinal tract cancers at various sites through genetic investigation. The findings of this research open up new perspectives and resources for exploring tumor prevention strategies and immunotherapeutic targets.
Journal • Immune cell
|
CD38 (CD38 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD14 (CD14 Molecule) • CD27 (CD27 Molecule) • CCR2 (C-C Motif Chemokine Receptor 2) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
1d
Potential pharmacological mechanisms of tanshinone IIA in the treatment of human neuroblastoma based on network pharmacological and molecular docking Technology. (PubMed, Front Pharmacol)
The results of molecular docking showed that Tan-IIA could interact with 10 targets: GRB2, SRC, EGFR, PTPN1, ESR1, IGF1, MAPK1, PIK3R1, AKT1 and IGF1R. This study analyzed the related pathways and targets of Tan-IIA in the treatment of human neuroblastoma, as well as the potential anticancer and anti-tumor targets and related signaling pathways of Tan-IIA, which provides a reference for us to find and explore effective drugs for the treatment of human neuroblastoma.
Journal
|
EGFR (Epidermal growth factor receptor) • ER (Estrogen receptor) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1) • IGF1 (Insulin-like growth factor 1) • MAPK1 (Mitogen-activated protein kinase 1) • PTPN1 (Protein Tyrosine Phosphatase Non-Receptor Type 1)
1d
Predictive value of procollagen c-protease enhancer protein on the prognosis of glioma patients. (PubMed, Heliyon)
Additionally, PCOLCE may exert its roles via several immune-related biological processes or pathways, such as leukocyte migration, activation of T cells, adaptive immune response, neutrophil-mediated immunity, NF-κB, and TNF signaling pathways. In conclusion, PCOLCE may be a new immune-related gene and regulate tumor development through immunological pathways.
Journal
|
CD4 (CD4 Molecule)
2d
Enhanced epithelial-mesenchymal transition signatures are linked with adverse tumor microenvironment, angiogenesis and worse survival in gastric cancer. (PubMed, Cancer Gene Ther)
While they significantly enriched multiple pro-cancerous gene sets, such as TGF-β signaling, hypoxia, and angiogenesis. The presence of EMT signature in a bulk tumor was linked to TGF-β signaling, hypoxia, and angiogenesis, and was also associated with poorer survival outcomes in GC patients.
Journal
|
CDH1 (Cadherin 1) • TGFB1 (Transforming Growth Factor Beta 1) • CDH2 (Cadherin 2)
|
CDH1 expression
2d
Co-targeting CD47 and VEGF elicited potent anti-tumor effects in gastric cancer. (PubMed, Cancer Immunol Immunother)
Our preclinical studies collectively offer substantiation that CD47 holds promise as a prospective target for gastric cancer, while also highlighting the potential of anti-angiogenic therapy to enhance tumor responsiveness to anti-CD47 immunotherapy.
Journal • IO biomarker
|
CD47 (CD47 Molecule) • FLT1 (Fms-related tyrosine kinase 1) • SIRPA (Signal Regulatory Protein Alpha)
|
CD47 expression • VEGFA expression
2d
PALOMA: A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies (clinicaltrials.gov)
P1, N=166, Recruiting, Janssen Research & Development, LLC | Trial primary completion date: Jan 2024 --> Oct 2024
Trial primary completion date • Metastases
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
EGFR exon 20 insertion • EGFR exon 20 mutation
|
Leclaza (lazertinib) • amivantamab SC (Ami-LC)
2d
Google Location History Following Oesophagectomy and/or Gastrectomy (clinicaltrials.gov)
P=N/A, N=3, Completed, Imperial College London | Recruiting --> Completed | N=300 --> 3
Trial completion • Enrollment change
2d
New P2 trial • Metastases
|
cisplatin • carboplatin • 5-fluorouracil • doxorubicin hydrochloride • capecitabine • albumin-bound paclitaxel • oxaliplatin • irinotecan • Jemperli (dostarlimab-gxly)
2d
The pathological roles and potential mechanisms of vascular endothelial growth factor receptor-3 in gastric cancer. (PubMed, J Int Med Res)
The molecular pathways associated with VEGFR-3-mediated pathological effects could be targets in the development of novel approaches for the diagnosis, prognosis and treatment of GC.
Journal
|
VEGFA (Vascular endothelial growth factor A) • FLT4 (Fms-related tyrosine kinase 4)